tradingkey.logo

Glaukos Corp

GKOS
View Detailed Chart

86.160USD

+0.065+0.08%
Close 08/01, 16:00ETQuotes delayed by 15 min
4.93BMarket Cap
LossP/E TTM

Glaukos Corp

86.160

+0.065+0.08%
Intraday
1m
30m
1h
D
W
M
D

Today

+0.08%

5 Days

-8.63%

1 Month

-16.75%

6 Months

-44.80%

Year to Date

-42.54%

1 Year

-25.74%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 15 analysts
BUY
Current Rating
123.500
Target Price
43.34%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

117
Total
6
Median
8
Average
Company name
Ratings
Analysts
Glaukos Corp
GKOS
15
Medtronic PLC
MDT
35
Stryker Corp
SYK
33
Abbott Laboratories
ABT
31
Zimmer Biomet Holdings Inc
ZBH
30
Dexcom Inc
DXCM
28
1
2
3
...
24

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

1m
15m
30m
1h
D
W
M
1m
15m
30m
D
Sell
Sell(9)
Neutral(1)
Buy(0)
Indicators
Sell(3)
Neutral(1)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-2.832
Sell
RSI(14)
25.692
Sell
STOCH(KDJ)(9,3,3)
20.052
Neutral
ATR(14)
3.406
Low Volatility
CCI(14)
-227.860
Oversold
Williams %R
84.982
Oversold
TRIX(12,20)
-0.344
Sell
StochRSI(14)
1.651
Oversold
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
90.996
Sell
MA10
93.275
Sell
MA20
97.468
Sell
MA50
97.664
Sell
MA100
96.063
Sell
MA200
118.714
Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.
Ticker SymbolGKOS
CompanyGlaukos Corp
CEOMr. Thomas William Burns
Websitehttps://www.glaukos.com
KeyAI